Extracellular matrix derived products from human placenta to engineer bone micro...
Extracellular matrix derived products from human placenta to engineer bone microtissues for in vitro disease models.
The aim of ‘AMNIOGEL’ is the development of human extracellular matrix (ECM) based materials, as radically innovative,
highly versatile human-derived platforms for 3D cell culture, microtissue development and disease models establ...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MicroBone
Novel 3D platforms to engineer bone microtissues for in vitr...
150K€
Cerrado
PID2019-106099RB-C41
MICROGELES BIOMIMETICOS PARA EL ESTUDIO DE LA GENERACION DE...
242K€
Cerrado
TissueEng
3D bioprinting construct for the diminishing of bone tumor a...
Cerrado
PID2021-123013OB-I00
BIOMATERIALES BIOINSPIRADOS PARA MODELAR LA INTERACCION CELU...
157K€
Cerrado
Design2Flow
Disposable well plate inserts and perfusion chambers for eas...
150K€
Cerrado
Información proyecto AMNIOGEL
Duración del proyecto: 27 meses
Fecha Inicio: 2020-07-22
Fecha Fin: 2022-10-31
Líder del proyecto
UNIVERSIDADE DE AVEIRO
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The aim of ‘AMNIOGEL’ is the development of human extracellular matrix (ECM) based materials, as radically innovative,
highly versatile human-derived platforms for 3D cell culture, microtissue development and disease models establishment. In
particular, we will develop 3D disease models that could be used as an enabling tool for personalized drug discovery,
increasing our understanding of the mechanisms behind bone cancer.
The proposed cutting-edge technology enables the culture of human cells in a physiologically relevant microenvironment for
applications in cell culture research, drug screening and development, cancer research, tissue engineering, replacement of
animal testing and therapeutic applications. The potential of this technology to reduce or completely replace use of animals
for biological screenings is expected to have a significant impact in the 3D cell culture market and pharmaceutical industry
by accelerating drug screening and development reducing associated costs. The innovation potential of our products is
based on the fact that contain human biochemical cues (vital for cell function), is a complete xeno-free solution (avoids
contamination) for human cell culture and easy to manipulate. It is worth mentioning that offers the possibility to be
personalised (using the patient’s own ECM) according to the customer needs. Moreover, our culture substrates are easily
processed in multiple geometries and in microarrays amenable to ‘organ-on- a-chip’ systems designed for high-throughput
screening (HTS) applications.